IO Combos By The Numbers

Over the past five years, pharma companies have cast an increasingly wide research net in search of cancer immunotherapy drug combinations that can help patients who have failed monotherapies.

Cancer immunotherapy has reshaped the oncology space. The drugs, which block a key mechanism among tumors that allows them to escape the attack of the immune system, have achieved long-lasting benefits in some patients, and activities across a broad array of tumor types. For all the good news, the drugs help only a small percentage of patients. Over the past five years, that wide applicability and frustratingly limited response has driven pharma companies to cast a wide research net in search of drug combinations that could produce a response in patients who fail monotherapies. (See Exhibit 1.)

“The obvious question is, 'are there approaches which can augment a response or excite a response in a patient who...

More from Deal-Making

More from In Vivo

EU Medtech Outlook: The View From MedTech Europe Experts

 
• By 

MedTech Forum 2025 was less MDR-focused than in previous years, as macro issues and exogenous threats were forced further into the center of medtech business thinking.

‘Confident In Lorundrostat’s Promise’: Mineralys CEO Talks Trials And Next Steps

 

In a conversation with In Vivo, CEO Jon Congleton discusses Mineralys’s data-rich journey toward an NDA filing, the significance of recent trial wins and how its candidate may offer a dual benefit in blood pressure and renal protection.

BioBytes: Qubit Pharmaceuticals Unveils Quantum AI Model For Drug Discovery

 
• By 

Qubit Pharmaceuticals and Sorbonne University launched a quantum AI model that could slash drug synthesis requirements and enable exploration of previously undruggable targets.